Standard Chartered Names Peter Burrill as Interim Group CFO Following Diego De Giorgi’s Exit 
American Airlines CEO to Meet Pilots Union Amid Storm Response and Financial Concerns 
DBS Expects Slight Dip in 2026 Net Profit After Q4 Earnings Miss on Lower Interest Margins 
Taiwan Says Moving 40% of Semiconductor Production to the U.S. Is Impossible 
Ancora Holdings Builds $200M Stake in Warner Bros Discovery, Targets Netflix Asset Sale Plan 
Lyft Shares Slide After Weak Q1 Profit Forecast and Surprise 2025 Operating Loss 
SpaceX Pivots Toward Moon City as Musk Reframes Long-Term Space Vision 
Air New Zealand Cabin Crew Strike Set for February 12–13 Amid Failed Talks 
Innovent Biologics Shares Rally on New Eli Lilly Oncology and Immunology Deal 
Treasury Wine Estates Shares Surge After U.S. Dispute Settlement and Earnings Upgrade 
CBA Shares Surge After Record Half-Year Profit as Rate Outlook Improves 
Petrobras Posts Record Oil Exports as Production Surge Fuels Global Expansion 
AST SpaceMobile Joins MSCI ACWI Index as Largest New Addition, Boosting Market Visibility 
xAI Co-Founder Jimmy Ba Departs as Elon Musk’s AI Startup Faces Turbulence 
Canadian Airlines Suspend Cuba Flights Amid Jet Fuel Shortage and U.S. Sanctions 
Alphabet Plans Rare 100-Year Sterling Bond to Fund AI Expansion 
Cloudflare Forecasts Strong Revenue Growth as AI Fuels Cloud Services Demand 
NEW YORK and MELBOURNE, Australia, Nov. 13, 2017 -- Mesoblast Limited (Nasdaq:MESO) (ASX:MSB;) today announced it will report financial results for the first quarter ended September 30, 2017 and provide a corporate update beginning at 4:30 pm ET on Tuesday, November 14, 2017 and 8:30 am AEDT on Wednesday, November 15, 2017.
The live webcast can be accessed via: http://webcasting.boardroom.media/broadcast/59ff897e6afa4a0577a982bb
The conference call will be accompanied by a slide presentation. Please log in approximately 15 minutes prior to the scheduled start time.
To access the call, dial 1 855 881 1339 (US), 1 800 558 698 (toll-free Australia) or +61 2 9007 3187 (outside of the US and Australia).
The conference identification code is: 303705.
The archived webcast will be available in the Events and Presentations section of the Investor page on the Company’s website – www.mesoblast.com
About Mesoblast
Mesoblast Limited (Nasdaq:MESO) (ASX:MSB) is a global leader in developing innovative cell-based medicines. The Company has leveraged its proprietary technology platform, which is based on specialized cells known as mesenchymal lineage adult stem cells, to establish a broad portfolio of late-stage product candidates. Mesoblast’s allogeneic, ‘off-the-shelf’ cell product candidates target advanced stages of diseases with high, unmet medical needs including cardiovascular diseases, immune-mediated and inflammatory disorders, orthopedic disorders, and oncologic/hematologic conditions.
For further information, please contact:
Julie Meldrum
Corporate Communications
Mesoblast Limited
T: +61 3 9639 6036
E: [email protected]
Schond Greenway
Investor Relations
Mesoblast Limited
T: +1 212 880-2060
E: [email protected]
